B-YOND Final Results Confirm Established Safety, Sustained Efficacy, and Extended Dosing Interval for Up to 4 Years of Treatment With rFIXFc in Previously Treated Subjects With Severe Hemophilia B

著录项

• 来源
  《Blood: The Journal of the American Society of Hematology》 |2018年第novaelatreatmentappr期|共4页
• 作者

  Ragni Margaret; Kulkarni Roshni; Pasi K. John; Fischer Kathelijn; Mahlangu Johnny; Shapiro Amy; Nolan Beatrice; Oldenburg Johannes; Matsushita Tadashi; Willemze Annemieke; Yuan Huixing; Rudin Dan;

  展开▼
• 作者单位

  Univ Pittsburgh Pittsburgh PA USA;

  Michigan State Univ E Lansing MI 48824 USA;

  Barts &

  London Queen Marys Sch Med &

  Dent Royal London Haemophilia Ctr London England;

  Univ Med Ctr Van Creveldklin Utrecht Netherlands;

  Univ Witwatersrand Fac Hlth Sci Haemophilia Comprehens Care Ctr Johannesburg South Africa;

  Indiana Hemophilia &

  Thrombosis Ctr Indianapolis IN USA;

  Our Ladys Childrens Hosp Dublin Ireland;

  Univ Bonn Inst Expt Haematol &

  Transfus Med Bonn Germany;

  Nagoya Univ Hosp Nagoya Aichi Japan;

  Sobi Stockholm Sweden;

  Bioverativ Waltham MA USA;

  Bioverativ Waltham MA USA;

  展开▼
• 收录信息
• 原文格式 PDF
• 正文语种 eng
• 中图分类 血液及淋巴系疾病;
• 关键词